Clinical trials: Nash
Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)
Glucagon Resistance in Patients With MASLD and T2DM
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).
- Trial name
- NCT07246421
- Testing
- Glugagon
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes…
- Trial name
- NCT03060538
- Testing
- BFKB8488A
- Where
- 18 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Genentech, Inc.
Non-Alcoholic Fatty Liver Disease
Motivational Interviewing in the Management of Non Alcoholic Fatty Liver Disease
The goal of this study is to assess if motivational counselling works to reduce the weight in participants with Non Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06348628
- Testing
- Motivational Interview
- Where
- Sri Lanka
- Volunteers
- 231 people
- Sponsor
- Madunil Anuk Niriella
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Nonalcoholic Steatohepatitis, Type 2 Diabetes Mellitus
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT02769091)
- Testing
- TEV-45478
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
- Trial name
- NCT05053165
- Testing
- LB-P6, LB-P8
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LISCure Biosciences
Non-alcoholic Fatty Liver Disease
The Metabolic Effects of Ginseng Oligopeptide Preparation on Non- Alcoholic Fatty Liver Disease With Obesity: a Randomized Controlled Double-blind Trial
To investigate the effect of ginseng oligopeptide on nonalcoholic fatty liver disease with obesity and clarify its intervention mechanism in theory, which will contribute to the prevention and treatment of non-alcoholic fatty…
- Trial name
- NCT06167902
- Testing
- Ginseng oligopeptide (Ginseng extract）, Maltodextrin
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)
This study will assess the inter-center reproducibility and accuracy of hepatic fat fraction measurements using up to two MRI-based methods.
- Trial name
- NCT01110577
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Alcoholic Fatty Liver Disease
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05426382
- Testing
- A digital care solution for patients with NAFLD
- Where
- 2 sites in Iceland
- Volunteers
- 38 people
- Sponsor
- Sidekick Health
NAFLD, NASH - Nonalcoholic Steatohepatitis
A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations
Liver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle. Fibrotic liver disease, culminating in cirrhosis, is frequently asymptomatic so it is common for a patient…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
- Trial name
- SUNN (NCT03726827)
- Testing
- Fibroscan screening
- Where
- United States
- Volunteers
- 1,006 people, healthy volunteers welcome
- Sponsor
- Fatty liver Foundation
Obesity
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction vitamin E supplementation on liver enzymes in overweight and obese children with non-alcoholic fatty liver disease as compared to placebo.
- Trial name
- NCT05905185
- Testing
- Tocotrienol-rich fraction vitamin E (TRF)
- Where
- Malaysia
- Volunteers
- 29 people
- Sponsor
- National University of Malaysia
Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight
Hepatoprotective Measures for Children at High Risk of NAFLD
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure.
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
- Trial name
- NCT06918080
- Testing
- Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
NAFLD, NASH With Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
- Conditions
- NAFLD, NASH With Fibrosis, Liver Fibrosis
- Trial name
- NCT05506488
- Testing
- Dasatinib 100 MG + Quercetin (1000 MG)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-Alcoholic Fatty Liver Disease
The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study
Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body.
- Trial name
- NLA2 (NCT05712603)
- Testing
- FIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
- Where
- 3 sites in Netherlands
- Volunteers
- 655 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non Alcoholic Fatty Liver
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non Invasive Methods.And correlation between lab and radiological methods .
- Trial name
- NCT04553796
- Testing
- fibroscan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non Alcoholic Steatohepatitis
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin and flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to…
- Trial name
- NCT03377153
- Testing
- hesperidin and flaxseed, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease, Body Composition
Predicting Obesity Consequences Using Body Measure and Urine Metabolomics
This is a prospective observational study which will recruit up to 1200 participants over a two-year period to investigate whether non-invasive methods such as bioelectrical impedance analysis parameters and urine metabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Body Composition, Electric Impedance
- Trial name
- NCT04989062
- Testing
- Fibroscan, Bioelectrical impedance analysis, Urine unclear magnetic resonance metabolomics
- Where
- Taiwan
- Volunteers
- 1,200 people
- Sponsor
- Chang Gung Memorial Hospital
Nonalcoholic Steatohepatitis, Liver Diseases
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
- Trial name
- NCT00267670
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.